WE CLAIM:

1. A method for treating chronic myelocytic leukemia (CML) in a patient, comprising administering to said patient a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one naked anti-granulocyte antibody.

2. The method of claim 1, wherein said anti-granulocyte antibody is an anti-NCA-90 antibody.

3. The method of claim 2, wherein said anti-NCA-90 antibody is MN-3.

4. The method of claim 1, wherein said anti-granulocyte antibody is an anti-NCA-95 antibody.

5. The method of claim 1, wherein said anti-granulocyte antibody is selected from the group consisting of MN-2, MN-15, NP-1 and NP-2.

6. A method for treating acute myelocytic leukemia (AML) or acute promyelocytic leukemia (APML) in a patient, comprising administering to said patient

a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one naked anti-granulocyte antibody, and

an inducing agent, wherein said inducing agent induces expression of antigens which are minimally displayed on the surface of myeloblasts.

7. The method of claim 1, wherein said anti-granulocyte antibody is selected from the group consisting of subhuman primate antibody, murine monoclonal antobody, chimeric antibody, humanized antibody and human antibody.

8. The method of claim 1, further comprising administering an immunoconjugate to said patient.

9. The method of claim 1, further comprising administering chemotherapy to said patient.

10. The method of claim 8, wherein said immunoconjugate comprises a cytokine moiety, wherein said cytokine moiety is selected from the group consisting of interleukin-1 (IL-1), IL-2, IL-3, IL-6, IL-10, IL-12, interferon-α, interferon-β, interferon-γ and GM-CSF.

11. The method of claim 8, wherein said immunoconjugate is radiolabeled.

12. The method of claim 11, wherein said radiolabeled immunoconjugate comprises a radionuclide selected from the group consisting of ^{198}Au, ^{32}P, ^{125}I, ^{131}I, ^{90}Y, ^{186}Re, ^{188}Re, ^{67}Cu, ^{211}At, ^{213}Bi and ^{225}Ac.

13. The method of claim 11, wherein said radiolabeled immunoconjugate further comprises a cytokine moiety, wherein said cytokine moiety is selected from the group consisting of interleukin-1 (IL-1), IL-2, IL-3, IL-6, IL-10, IL-12, interferon-α, interferon-β, interferon-γ and GM-CSF.

14. The method of claim 8, wherein said immunoconjugate is an antibody fusion protein.

15. The method of claim 14, wherein antibody fusion protein is an antibody-immunomodulator fusion protein or an antibody-toxin fusion protein.

16. The method of claim 8, wherein said immunoconjugate is a conjugate of (i) an anti-NCA 90 antibody and RNase or (ii) an anti-CD33 antibody and calicheamicin.

17. The method of claims 9, wherein said chemotherapy comprises the administration of at least one drug selected from the group consisting of daunorubicin, cytarabine, 6-thioguanine, mitoxantrone, diaziquone, idarubicin, homoharringtonine, Amsacrine, busulfan, hydroxyurea, cyclophosphamide, etoposide, vincristine, procarbazine, prednisone, carmustine, doxorubicin, methotrexate, bleomycin, dexamethasone, phenyl butyrate, brostatin-1, calicheamicin and leucovorin.

18. The method of any of claim 1, wherein said therapeutic composition comprises two or more naked anti-granulocyte antibodies.

19. The method of any of claim 1, further comprising administering an anti-CD33 antibody.

20. The method of claim 19, wherein said anti-CD33 antibody is M-195.

21. The method of claim 1, further comprising administering an anti-CD15 antibody.

22. The method of claim 6, wherein said inducing agent is retinoic acid or arsenic oxide.

23. The method of claim 8, wherein said immunoconjugate is administered before, concurrently, or after administration of said naked antibody.

24. The method of claim 9, wherein said chemotherapy is administered before, concurrently, or after administration of said naked antibody.